"Many doctors screen women for cervical cancer every year rather than waiting the recommended 3 years after a normal test result, a recent study finds. However, according to the Centers for Disease Control and Prevention, annual screening offers no real advantage over less-frequent tests. MORE "
Many doctors screen women for cervical cancer every year rather than waiting the recommended 3 years after a normal test result, a recent study finds. However, according to the Centers for Disease Control and Prevention, annual screening offers no real advantage over less-frequent tests.
Guidelines from the American Cancer Society and other organizations recommend screening women 30 years of age and older for cervical cancer using the HPV co-test-human papillomavirus (HPV) testing and the Papanicolaou smear. If both results are normal, the guidelines recommend a 3-year interval between co-tests. To assess how healthcare providers use the tests, researchers analyzed data from about 600 office-based doctors and hospital departments collected through the Centers for Disease Control and Prevention’s (CDC’s) National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey. They found that about 51% of providers ordered the HPV co-test but fewer than 15% recommend the next Pap test in 3 years for women with normal co-test results and a documented normal screening history.
“Overall, annual cervical cancer screening continues to be a common recommendation, regardless of whether a screening history has been established or an HPV test has been ordered,” the authors of the study conclude.
The researchers evaluated provider response to 3 scenarios involving a woman between 30 and 60 years of age: 2 consecutive normal Pap tests but no HPV tests; 2 normal Pap tests and a negative HPV test; and a negative HPV test but no recent Pap tests. Although guidelines recommend retesting in 3 years for all 3 situations, 67% to 85% of doctors said they would retest in a year in each scenario.
The study was published online June 12 in the American Journal of Obstetrics and Gynecology.
Unraveling preeclampsia: Insights into heterogeneity and intravascular inflammation
April 22nd 2024A recent study delved into the intricate clusters of term preeclampsia, shedding light on its diverse manifestations and the pivotal role of intravascular inflammation, paving the way for improved classification and management strategies.
Read More
Personalized opioid protocol for cesarean deliveries: Reduced prescriptions reported
April 19th 2024A recent suggests that implementing a personalized opioid prescription protocol significantly reduces total morphine milligram equivalents and the number of opioid tablets prescribed at discharge following cesarean delivery.
Read More
Long-term mortality risks for women with adverse pregnancy outcomes
April 19th 2024A recent study revealed that women who experience major adverse pregnancy outcomes face heightened long-term mortality risks, shedding light on the need for comprehensive understanding and preventative measures in women's health.
Read More